மருத்துவ ப்ரோக்ர்யாம் தலைவர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருத்துவ ப்ரோக்ர்யாம் தலைவர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருத்துவ ப்ரோக்ர்யாம் தலைவர் Today - Breaking & Trending Today

ViroCell, the UK's first clinical trial focused viral vector manufacturer, announces its official launch


ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch
ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch
ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces its official launch. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy sector (“CGT”).
ViroCell aims to be the supplier of choice for viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials. ViroCell has assembled the UK’s most experienced viral vector manufacturing team to support its heavy operational demand and is now building out further manufacturing cap ....

United Kingdom , City Of , Peter Harper , Jean Pierre Bizzari , Virocell Biologics , Farzin Farzaneh , Johnw Hadden , Evren Alici , Ferid Murad , Kate Bingham , Edmund Truell , Oxford Astrazeneca , Mark Lowdell , Paulg Richardson , King College London , Clinical Oncology Development , Contract Development , Truell Conservation Foundation , Founder Of The Oncology Department At Guy , Jerome Lipper Multiple Myeloma Center , Manufacturing Organization , Group Head , Clinical Research , Welbeck Health Partners , Department Of Medicine , Clinical Program Leader ,

FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class Refractory Multiple Myeloma


Share this article
Share this article
WALTHAM, Mass., March 1, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO),  a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. This indication has been granted under accelerated approval based upon the HORIZON trial. PEPAXTO is the first anticancer peptide-drug conjugate approved in multiple myeloma. ....

United States , Los Altos , Dana Farber Cancer Institute , Marty Duvall , Sarah Connors , Linda Holmstr , Jakob Lindberg , Paulg Richardson , Us Communications , Jerome Lipper Multiple Myeloma Center , Oncopeptides Inc , Drug Administration , Clinical Research , Clinical Program Leader , Nasdaq Stockholm , Dana Farber Cancer , Overall Response Rate , Median Duration , Chief Scientific Officer , Multiple Myeloma , Chief Executive Officer , New Drug Application , Triple Class Refractory , Director Investor Relations , Oncopeptides Ab , ஒன்றுபட்டது மாநிலங்களில் ,